Zhejiang Xianju Pharmaceutical Co., Ltd. (002332.SZ) Latest Company News

Sep 10, 2026, 09:03 UTC
Xianju Hongju Microfinance Co., Ltd., a 30%-owned associate of Zhejiang Xianju Pharmaceutical, plans to apply to regulators to exit the microfinance business and its shareholders intend to reduce capital pro rata after approval.
Source:
- finance.sina.cn
Sep 10, 2026, 08:44 UTC
Zhejiang Cuize Pharmaceutical Technology plans to increase registered capital by 420,264 yuan, subscribed by Zhejiang Zizi Xian'an Yaoxin Equity Investment Partnership (Limited Partnership) for 20 million yuan in cash, while Xianju Pharmaceutical waived its preferential subscription right, reducing its stake from 32.1957% to 31.4512%.
Source:
- finance.sina.cn
Sep 8, 2026, 13:54 UTC
Xianju Pharmaceutical announced a cash dividend of 1 yuan per 10 shares for the first half of 2026, with record date September 15, 2026.
Source:
- wap.eastmoney.com
Aug 27, 2026, 12:19 UTC
Xianju Pharmaceutical proposed a cash dividend of 1 yuan per 10 shares (tax included) to all shareholders.
Source:
- finance.sina.cn
Aug 27, 2026, 12:19 UTC
Xianju Pharmaceutical disclosed its semi-annual report on August 27, reporting net profit attributable to shareholders of 245 million yuan, down 20.67% year-on-year.
Source:
- finance.sina.cn
Aug 10, 2026, 08:55 UTC
Xianju Pharmaceutical's subsidiary Newchem signed a settlement agreement with Gedeon Richter and Estetra over a supply agreement dispute and received 10 million euros.
Source:
- finance.sina.cn
Jul 22, 2026, 11:12 UTC
Xianju Pharmaceutical announced that as of July 22, 2026, it has repurchased 9.8929 million shares, representing 1.0001% of total shares, for a total cost of 81.9068 million yuan.
Source:
- finance.sina.cn
Jul 10, 2026, 09:18 UTC
Xianju Pharmaceutical announced that 5 of its products, including progesterone capsules, were newly included in the 2026 edition of the National Essential Drugs List, effective September 1, 2026.
Source:
- finance.sina.cn

002332.SZ

Xianju Hongju Microfinance Co., Ltd., a 30%-owned associate of Zhejiang Xianju Pharmaceutical, plans to apply to regulators to exit the microfinance business and its shareholders intend to reduce capital pro rata after approval.

Xianju Pharmaceutical announced a cash dividend of 1 yuan per 10 shares for the first half of 2026, with record date September 15, 2026.

Xianju Pharmaceutical proposed a cash dividend of 1 yuan per 10 shares (tax included) to all shareholders.

Xianju Pharmaceutical disclosed its semi-annual report on August 27, reporting net profit attributable to shareholders of 245 million yuan, down 20.67% year-on-year.

Xianju Pharmaceutical's subsidiary Newchem signed a settlement agreement with Gedeon Richter and Estetra over a supply agreement dispute and received 10 million euros.

Xianju Pharmaceutical announced that as of July 22, 2026, it has repurchased 9.8929 million shares, representing 1.0001% of total shares, for a total cost of 81.9068 million yuan.

Xianju Pharmaceutical announced that 5 of its products, including progesterone capsules, were newly included in the 2026 edition of the National Essential Drugs List, effective September 1, 2026.